We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
On this page, you will find the most up-to-date notices regarding current events and their impact on West Operations.
West Pharmaceutical Services, Inc. detected a network systems issue on Monday, May 4, 2026, which was subsequently determined to be a cyberattack. West promptly activated its incident response protocols, including proactively taking its systems offline for containment, notifying law enforcement, and engaging external cyber-forensic experts. Our investigation remains ongoing, and we are working diligently to determine the nature and scope of the incident, including the extent to which any data was affected.
Our teams are making good progress with restoration efforts to return to full operations while minimizing potential impact to our customers. Core enterprise systems are now operational globally, and critical restart activities are underway and proceeding in a controlled and phased manner.
Ensuring continuity of service remains our top priority. We will continue to provide timely updates as additional information becomes available.
Last Updated May 7, 2026
West is committed to providing timely and transparent communication to all stakeholders regarding the ongoing events in the Middle East and their potential impact on our manufacturing operations at the West Israel site, as well as on our global supply chain.
At this time, we can confirm that the West Israel site, along with our key suppliers and partners, remains operational with minimal disruption to manufacturing and supply chain activities.
In addition, our primary logistics lanes across the global network remain open and operational. Our Logistics team is working closely with transportation partners and has implemented proactive risk mitigation measures to minimize potential delays. While air freight conditions remain dynamic, the actions taken to date have limited the impact on our global operations.
We appreciate your understanding as the situation continues to evolve. We will provide additional updates should any developments arise that may affect your business operations.
Last Updated March 17, 2026
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
The need to provide vaccines for the SARS-CoV-2 pandemic has presented the pharmaceutical industry with unprecedented challenges. Among them are accelerated timelines for development/approval and unanticipated volumes for manufacture/delivery. Ordinarily for a new drug product, there is ample time for selecting the primary package system and establishing component availability.
Marisa Leuzzi, Senior Specialist, Global Communications, from our Exton Headquarters, is one of the growing number of coronavirus survivors. Her experiences with her illness is not uncommon – but what she did after her recovery to keep her family whole is remarkable.
English
Chinese
